media – Page 119 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Rushing towards NASDAQ, another Chinese new drug company has arrived

In June 2023, Astellas Pharma Inc. announced a research collaboration and exclusive selection agreement with Cullgen for a total amount of up to $1.9 billion, with a $35 million advance payment and $85 million option exercise fee. Used for collaborative development of potential first in class protein degrading agents. On November 13, 2024, Pulmatrix (NASDAQ: PULM) announced a merger agreement with Cullgen. At present, Cullgen has three degradation agent projects that are about to or are in the process of initiating phase I clinical trials. Two of the projects are used to treat cancer, and one project is used to treat acute and chronic pain. The merged company is expected to have approximately $65 million in cash and cash equivalents upon completion of the merger, providing funding for multiple clinical milestones and expected to sustain operations until 2026. CG001419 is an oral pan TRK degrader in the clinical stage, and ...
- Source: drugdu
- 150
- November 27, 2024
MNC applauded, Biotech loosened up

On November 6, Trump scored twice and won the new US presidential election. The White House once again welcomed this Republican familiar. For a long time, the Republican Party has been more conservative and “cold” towards the biopharmaceutical industry than the Democratic Party. Trump is no exception: the Republican Party takes the “small government” route, and he has long focused his position on opposing government intervention. For pharmaceutical companies, this is a good thing: a relatively loose policy environment is more conducive to the free development of the industry. A pharmaceutical practitioner in the United States explained the industry sentiment in this way: “Generally speaking, Pharma believes that Trump may revise the previous radical IRA (Inflation Reduction Act) and re-emphasize market logic; some biotechs are on the sidelines; the worst may be some public research institutions and public health institutions. According to Trump’s previous attitude, their funding will be much ...
- Source: drugdu
- 161
- November 27, 2024
Medtronic acquires the endoscopy giant

On November 21, Fortimedix Surgical announced that it had been successfully acquired by Medtronic. Fortimedix is known for its unique articulated instrument technology, which subverts tradition and is committed to setting a benchmark in the field of robotic and non-robotic endoscopic treatment and minimally invasive surgery. “We are delighted to announce that Fortimedix Surgical has officially joined the Medtronic family,” the company shared on LinkedIn. “This collaboration will apply our articulated instrument technology to patient treatment and open a new chapter. We look forward to shining on the Medtronic platform.” The official website of Fortimedix shows that the company uses full laser cutting technology to create a multi-layer nested and welded product architecture. This innovative process magically transforms ordinary metal tubes into flexible articulated shafts, which have hundreds of precision moving parts after assembly, and are powerful and complex. This proprietary technology has shown great value in endoscopic treatment and ...
- Source: drugdu
- 297
- November 27, 2024
TJ Pharma’s Subsidiary Approved for New Specification of Potassium Chloride Injection

Financial Center, November 25 – TJ Pharma (600488) announced that its subsidiary has received approval for a new specification of potassium chloride injection and has passed the consistency evaluation for generic drugs. The announcement indicated that the subsidiary in Hubei has recently received an approval notice from the National Medical Products Administration for the addition of a new specification of 10ml:1.5g for potassium chloride injection. The drug is used to treat and prevent hypokalemia, particularly in cases where oral potassium supplementation is not possible. So far, Hubei TJ Pharma has invested approximately 5.57 million yuan in research and development costs for the potassium chloride injection project. According to data from Mianei Network, the domestic sales of potassium chloride injection were 612 million yuan and 661 million yuan in 2022 and 2023, respectively. The addition of the new specification and passing the consistency evaluation will help enrich medication options for patients, ...
- Source: drugdu
- 142
- November 27, 2024
Anke Biotechnology’s Human Growth Hormone Injection New Indication Application Accepted

Beijing Business News (Reporter Ding Ning) – On the evening of November 25, Anke Biotechnology (300009) announced that it had received the “Acceptance Notice” administrative licensing document from the National Medical Products Administration. The company’s supplementary application for a new indication of its human growth hormone injection for small for gestational age (SGA) children has been accepted. Anke Biotechnology stated that its human growth hormone injection features no preservatives and is user-friendly. This new indication adds to the eight previously approved indications for the product; if approved, it will help meet the clinical medication needs of such children and enhance the company’s market competitiveness. https://finance.eastmoney.com/a/202411253250010353.html
- Source: drugdu
- 111
- November 27, 2024
Hong Kong Pharmaceutical ETF (513700) has risen nearly 11% in the past three months, emphasizing the structural opportunities in the differentiated pharmaceutical industry

As of 09:49 on November 25, 2024, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) has risen strongly by 1.05%, with component stocks such as Zaiding Pharmaceutical (09688) rising by 7.79%, Kelombotai Bio-B (06990) rising by 5.24%, Kangfang Bio-B (09926) rising by 3.67%, and stocks such as WuXi AppTec (02268) and Kangnuoy-B (02162) following suit. The Hong Kong Pharmaceutical ETF (513700) rose by 0.99%. Over time, as of November 22, 2024, the Hong Kong Pharmaceutical ETF has risen by 10.99% in the past three months. In terms of scale, the Hong Kong Pharmaceutical ETF has grown by 36.8335 million yuan in the past week, achieving significant growth. From a valuation perspective, the latest P/E ratio (PE-TTM) of the China Securities Hong Kong Stock Connect Medical and Health Composite Index tracked by the Hong Kong Pharmaceutical ETF is only 27.24 times, at the 16.77% percentile in the ...
- Source: drugdu
- 180
- November 26, 2024
Kunyao Group’s Class 1 new drug is coming! Seize the market worth 210 billion yuan

Recently, the CDE official website showed that KPC000154 tablets, a Class 1 new drug declared by Kunming Pharmaceutical Group, have obtained implied approval for clinical trials, with indications for non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive system and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets (detailed statistical scope at the end of this article) will exceed 210 billion yuan in 2023. Reference No. Drug name Applicant name Indication Registration classification CXHL2400923 KPC000154 pills KPC (Hengqin, Zhuhai) Technology Co., Ltd; KPC Pharmaceuticals Inc. NASH 1 CXGL2400922 KPC000154 pills KPC (Hengqin, Zhuhai) Technology Co., Ltd; KPC Pharmaceuticals Inc. NASH 1 KPC000154 tablets are a Class 1 innovative drug independently developed by Kunming Pharmaceutical Group. Its clinical application was accepted by CDE in September 2024 and was recently approved for clinical use in the treatment of non-alcoholic fatty liver disease. According ...
- Source: drugdu
- 212
- November 26, 2024
Siemens Healthineers and Densburg Sinode collaborate to install the world’s first dental-dedicated MRI

Recently, Denspensinord and Siemens Healthineers announced a partnership with the School of Dentistry at the University of Minnesota to install the first dental dedicated MRI (ddMRI) in the United States. It is reported that the research project will explore the planned MAGNETOM Free The potential features of Max Dental Edition for dental imaging and diagnosis include the potential advantages of ddMRI in preventing and correcting oral care. Based on the proven outstanding achievements of the University of Minnesota Magnetic Resonance Research Center in MRI research, Denspensinord and Siemens Healthineers have decided to install the system at the school’s School of Dentistry for research purposes. 01. Installation of the first dental specific MRI According to the data, the MAGNETOM Free. Max Dental Edition MRI system is a joint research initiative between Densburg Sinode and Siemens Healthineers aimed at exploring new opportunities in the field of dental imaging. By utilizing MRI to ...
- Source: drugdu
- 128
- November 26, 2024
KPC Pharmaceuticals Inc.’s Class 1 new drug is about to seize the market

Recently, the CDE official website showed that KPC000154 tablets, a Class 1 new drug declared by Kunming Pharmaceutical Group, have obtained implied approval for clinical trials, with indications for non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive system and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets (detailed statistical scope at the end of this article) will exceed 210 billion yuan in 2023. KPC000154 tablets are a Class 1 innovative drug independently developed by Kunming Pharmaceutical Group. Its clinical application was accepted by CDE in September 2024 and was recently approved for clinical use in the treatment of non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive systems and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets will remain above 210 billion yuan from 2021 to 2023, but will continue to ...
- Source: drugdu
- 248
- November 26, 2024
Haobo Medical ASO treats hepatitis B, with a negative conversion rate of over 60%

Hepatitis B, as one of the common infectious diseases worldwide, has long troubled the medical community and patients. Although a variety of treatments are available, achieving functional cure of hepatitis B has always been the focus and difficulty of medical research. Recently, according to a report by “Liver Time”, Haobo Pharmaceutical has made breakthrough progress in the treatment of hepatitis B through its independently developed ASO therapy AHB-137. Clinical trial data shows that the HBsAg negative conversion rate of AHB-137 exceeds 60%. It provides new hope for the treatment of hepatitis B. AHB-137 is carefully developed by Haobo Pharmaceutical through its unique scientific research platform Med-Oligo™. This ASO (antisense oligonucleotide) drug has shown remarkable results in clinical trials for the treatment of hepatitis B. According to public data, among patients with baseline HBsAg levels of 100-3000IU/ml, after 12 weeks of treatment, 62% and 43% of patients in the 300 mg ...
- Source: drugdu
- 481
- November 26, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.